HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...
Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...
Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...
Hosted on MSN1mon
Many adults stop GLP-1 therapy within a year with low restart rates, analysis findsDiscontinuation was defined as 60 days without any GLP-1 RA on hand. Reinitiation was defined as the first fill of any GLP-1 RA after discontinuation. Patients were followed for up to two years ...
The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.
The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor ... short amount of 12-weeks already proved that its GLP-1 RA MET-097i already attained a mean placebo adjusted ...
Three studies attempting to tease out the potential effects of glucagon-like peptide 1 receptor agonists (GLP-1 RA) taken before or during pregnancy were presented at the annual meeting of the ...
GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D ...
GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
Adults aged 66 years or older with T2D initiating treatment with a GLP-1 RA were propensity score-matched to those initiating treatment with an SGLT-2i (14,665 matched pairs) or a DPP-4i (13,711 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results